DRAPER, Utah, Jan. 6, 2021 /PRNewswire-PRWeb/ -- Xevant completed a new investment round and is preparing to expand its scope in 2021. The growth financing, led by industry leaders Tech Council Ventures (TCV), Martinson Ventures (MV), and Boston Millennia Partners (BMP), positions Xevant to expand its team, enhance products, and provide tailored solutions to a broader market.
Xevant CEO Brandon Newman said, "We are pleased to partner with proven leaders in the Health Tech investment community. Their contributions span well beyond investment and their influence has already made a significant and lasting impact on Xevant's long-term success."
As the most comprehensive, independent pharmacy analytics platform available, Xevant gives users the ability to automate decades-old analytic processes and deliver tailored solutions resulting in optimized performance for their clients and tremendous efficiencies for their businesses.
TCV Managing Partner Jim Gunton stated, "Tech Council Ventures is excited to support a proven entrepreneur and business developing automated software that analyzes data trends, alerts users of immediate savings opportunities, and pinpoints areas of improvement in an effort to support all stakeholders in the pharmacy benefits industry." Dana Callow of BMP said, "We look forward to working with the Xevant team as their leadership in the healthcare analytics sector is effectively meeting customers' needs and altering how we approach drug spend entirely." John Martinson of MV added, "Xevant is poised for rapid expansion."
Xevant's unique ability to positively impact all stakeholders of pharmacy benefits will now be further enhanced with this round of investment giving them the ability to affect the healthcare market in ways never thought possible.
About Xevant: Founded in 2017, Xevant is a groundbreaking data analysis platform that automates daily claims information and insights in real-time, delivering solutions that create value for customers in the payer, TPA, consulting, broker, and PBM markets. By converting data into immediate savings opportunities, this dynamic interface provides crucial insights and automation that helps improve drug costs and outcomes.
Contact: Greg Heaps
Xevant
[email protected]
Media Contact
Greg Heaps, Xevant, +1 801-634-5717, [email protected]
SOURCE Xevant
Share this article